BioLife Solutions Reiterates Guidance
BioLife Solutions Reiterates Guidance
BioLife 解决方案重申指导方针
2024 Revenue Guidance
2024 年收入指导
BioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR product line and do not include revenue from the freezer product line (GCI and CBS).
BioLife Solutions确认其2024年的收入预期为9,550万美元至1亿美元。这是基于对BioLife细胞处理和生物存储服务平台的预期，该平台现在包括其ThawStar产品线的结果，不包括冷冻产品线（GCI和CBS）的收入。
- Cell Processing platform: $66.0 million to $68.5 million, an increase of 0% to 4% compared with 2023. Compared with annualizing the second half of 2023 revenue run rate, the growth would be 17% to 22%
- Biostorage Services platform: $29.5 million to $31.5 million, an increase of 5% to 12% compared with 2023. This platform now includes the ThawSTAR automated thawing product line. Without ThawSTAR, the growth rate would be 10% to 16%.
- 细胞处理平台：6,600万美元至6,850万美元，与2023年相比增长了0％至4％。与2023年下半年的年化收入运行率相比，增长将为17％至22％
- 生物存储服务平台：2950万美元至3,150万美元，与2023年相比增长了5％至12％。该平台现在包括ThawStar自动解冻产品线。如果没有解冻之星，增长率将为10％至16％。